Education
About Us
Working with TipRanks
Follow Us
Avacta Group PLC (GB:AVCT)
LSE:AVCT
AVCT Stock Chart & Stats
65.00p
-0.10p(-0.19%)
At close: 4:00 PM EST
65.00p
-0.10p(-0.19%)
Day’s Range― - ―
52-Week Range26.00p - 84.00p
Previous CloseN/A
Volume371.99K
Average Volume (3M)3.07M
Market Cap
£253.69M
Enterprise Value243.96M
Total Cash (Recent Filing)£12.64M
Total Debt (Recent Filing)£20.40M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Apr 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding440,415,500
10 Day Avg. Volume4,236,507
30 Day Avg. Volume3,069,625
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)17.61
Price to Sales (P/S)1446.46
P/FCF Ratio-6.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.85
Revenue Forecast (FY)£118.60M
Bulls Say, Bears Say
Bulls Say
Platform & Target CoverageAvacta's proprietary Affimer/pre|CISION platform, validated by Tempus showing FAP expression in 90% of solid tumors, supports a broad addressable oncology opportunity. This structural validation strengthens partner interest, licensing prospects and long-term pipeline utility across many tumor types.
Clinical ProgressProgression of lead program to Phase Ib and upcoming first-patient dosing for FAP-exatecan materially de-risks the pipeline over the medium term. Achieving clinical milestones creates durable value inflection points, improves partner and investor confidence, and supports future commercialization paths.
Financing Actions & RunwayManagement has secured renegotiation of convertible debt and a GBP 6.5m raise to cover bond payments, extending runway into Q1 2026. These structural financing moves indicate an ability to manage covenant stress and fund near-term development milestones without immediate program cancellations.
Bears Say
Weak Balance Sheet & LeverageA deteriorating balance sheet with rising leverage and a weakened equity ratio constrains strategic flexibility. Higher indebtedness increases financing costs, elevates covenant and refinancing risk, and can force dilutive funding or scaled-back R&D, impairing long-term execution capacity.
Persistent Cash BurnConsistent negative operating and free cash flow and sizeable H1 2025 outflows indicate structural cash burn. The company remains dependent on external funding cycles; this persistent deficit raises dilution risk, limits ability to self-fund late-stage trials, and pressures long-term sustainability.
Lack Of Secured PartnershipsThe absence of confirmed strategic partnerships is a durable execution risk for a small biotech. Without external pharma collaborators to fund or co-develop assets, Avacta faces greater financing burdens, slower scale-up of clinical programs, and reduced commercialization reach over the medium term.
Avacta Group plc News
AVCT FAQ
What was Avacta Group PLC’s price range in the past 12 months?
Avacta Group PLC lowest share price was 26.00p and its highest was 84.00p in the past 12 months.
What is Avacta Group PLC’s market cap?
Avacta Group PLC’s market cap is £253.69M.
When is Avacta Group PLC’s upcoming earnings report date?
Avacta Group PLC’s upcoming earnings report date is Apr 16, 2026 which is in 55 days.
How were Avacta Group PLC’s earnings last quarter?
Avacta Group PLC released its earnings results on Sep 30, 2025. The company reported -0.042p earnings per share for the quarter, missing the consensus estimate of N/A by -0.042p.
Is Avacta Group PLC overvalued?
According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued.
Does Avacta Group PLC pay dividends?
Avacta Group PLC does not currently pay dividends.
What is Avacta Group PLC’s EPS estimate?
Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avacta Group PLC have?
Avacta Group PLC has 440,415,500 shares outstanding.
What happened to Avacta Group PLC’s price movement after its last earnings report?
Avacta Group PLC reported an EPS of -0.042p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.667%.
Which hedge fund is a major shareholder of Avacta Group PLC?
Currently, no hedge funds are holding shares in GB:AVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avacta Group plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-67.26%
Trailing 12-Months
Company Description
Avacta Group PLC
Avacta Group plc is a biotechnology company based in the UK that focuses on developing innovative therapies and diagnostics for various diseases, including cancer. The company operates primarily in the life sciences sector, utilizing its proprietary Affimer technology, which is a platform for the development of therapeutic and diagnostic products. Avacta's core offerings include Affimer proteins that can be used for both research and therapeutic applications, as well as its development of a novel cancer immunotherapy and diagnostic tests for COVID-19 and other diseases.
Technical Analysis
Nuformix Plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―